In our standard antibody production procedure, we will add an additional N-terminal or C-terminal cysteine for carrier protein conjugation. If the peptide sequence is not at terminus of the protein, we will N-acetylate or C-amidate the other end of the peptide antigen to mimic the native conformation. But if you prefer to leave the end free, please select no modification. Or please select "GenScript's choice".
Traditional antibody production is based primarily on either chromatographically purified peptides or on expressed or native proteins separated via gel electrophoresis. The very best immunogens are peptides synthesized de novo for the sole purpose of that specific antibody generation project. Only a few antibody generation systems employ these superior immunogens. This may be because of the high cost of peptide synthesis and immunogen peptide sequence information. However, GenScript's peptide synthesis technology, aided by cutting-edge bioinformatics, can not only provide the highest quality in peptide immunogens but do so at the most reasonable and competitive price in the industry.
GenScript synthetic peptides, in addition to their minimal cost and excellent purity, can be used to produce antibodies in a variety of species, such as rabbits, goats, sheep, mice, rats, and chicken. During the peptide synthesis process, post-translational modifications (PTMs) can be added at specific sites along the peptide chains. This increases of the selectivity of the antibody production process.
The use of GenScript synthetic peptides as immunogens in the manufacturing of polyclonal antibodies has numerous advantages relative to the use of protein immunogens. First, with the combination of synthetic peptides and affinity purification, epitope-specific and epitope-limited antibodies can be produced by targeting specific epitopes. Second, separate antibodies can be coupled to several regions of the same protein, enabling the design of specific assays to quantify the amount of the protein present. Third, post-translational modifications, such as phosphorylation, can be introduced more reliably. These enable the production of phosphorylation state-specific antibodies, also known as phosphospecific antibodies. Finally, there are GenScript's competitive prices.